Studies are needed to investigate the significance of mutations in commonly mutated cell cycle-regulating genes like TP53, MYC, BCL2, and BCL6 and DDR genes like ATM. Additionally, associations between lymphoma and epigenetic modifiers offer clinically useful biomarkers given their high frequency and connection to disease development. This evidence concerns the gene TP53 and lymphoma.